ONCO Onconetix, Inc.
USHealthcareAs of 2026-07-02
Why ONCO matters now
Onconetix, Inc. (ONCO) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.96 with -11.53% on the session and $319.2K in market capitalization; recent performance reads 1-month -19.32% and YTD -98.79%.
The latest financial table shown here is Q1 2026, with revenue of $21.5K, net income of $-4.2M, and EPS of $-6.71. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3108.3%.
The latest indexable market news headline is "Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes HRT FINANCIAL LP filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.05
P/S
0.43
EV/EBITDA
0.34
DCF Value
$1.39
FCF Yield
-3108.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
79.6%
Operating Margin
-922.7%
Net Margin
-1319.6%
ROE
-105.5%
ROA
-65.4%
ROIC
-56.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $21.5K | $-4.2M | $-6.71 |
| Q4 2025 | $303.6K | $5.7M | $1.04 |
| FY 2025 | $815.4K | $-14.0M | $-4.73 |
| Q3 2025 | $303.7K | $-8.8M | $-1.79 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.72
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.